The Glucagon Emergency Kit is an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes.
This kit includes Glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of Sterile Water for Injection, USP.
The Glucagon Emergency Kit is designed to be convenient and easy to use. Patients can carry it with them, so it is available should they experience severe hypoglycemia.
The bright orange case makes it easy for a patient or caregiver to find it and act quickly. To help make the Glucagon Emergency Kit more affordable, there is a co-pay assistance programme for patients who qualify.
Fresenius Kabi is also making injection training kits available to health care providers to help educate patients.
Glucagon for Injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients.
The company's US headquarters is in Lake Zurich, Illinois. The company's global headquarters is in Bad Homburg, Germany.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial